Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse



Status:Completed
Conditions:Psychiatric, Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 55
Updated:9/16/2018
Start Date:October 2013
End Date:September 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The research proposed in this application will determine the initial efficacy, safety and
tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a
pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human
laboratory study will be conducted. The proposed study is innovative and important because it
will provide the impetus for the conduct of double blind, placebo-controlled trials to
further demonstrate the efficacy of combined oxazepam and naltrexone for managing
methamphetamine dependence.


Inclusion Criteria:

- Lifetime methamphetamine use

Exclusion Criteria:

- Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians
deem clinically significant

- Current or past histories of substance abuse or dependence that are deemed by the
study physicians to interfere with study completion

- History of serious physical disease, current physical disease, impaired cardiovascular
functioning, chronic obstructive pulmonary disease, history of seizure or current or
past histories of serious psychiatric disorder that in the opinion of the study
physician would interfere with study participation will be excluded from participation

- Females not currently using effective birth control

- Contraindications to methamphetamine (Desoxyn®), oxazepam (Serax®) or naltrexone
(Revia®)
We found this trial at
1
site
University of Kentucky Medical Center
740 South Limestone Street
Lexington, Kentucky 40536
Principal Investigator: Craig R Rush, Ph.D.
Phone: 859-257-5388
?
mi
from
Lexington, KY
Click here to add this to my saved trials